P2Y12 inhibitor monotherapy is the preferred strategy over aspirin following shortened dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS), according to a comprehensive analysis that could reshape clinical decision-making — though experts caution that the "sweet spot" for optimal treatment duration remains elusive.